Feature | Cardiac Imaging | March 22, 2019| By Greg Freiherr

Siemens Joins GE With Launch of Cardiac CT Scanners

CTs are loaded with apps but priced for outpatient centers

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve).

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve). Photo by Greg Freiherr

Greg Freiherr

Greg Freiherr

Reflecting a trend toward the increased use of computed tomography (CT) in cardiology, Siemens Healthineers launched a CT scanner optimized for cardiac scanning at the American College of Cardiology conference (#ACC19). The new Siemens’ CT, a version of its Go platform, follows GE Healthcare’s launch two years ago of the CardioGraphe, a CT scanner that GE highlighted at this year’s ACC conference.

Both systems are intended primarily for sale to outpatient centers. Compact and optimized for cardiac application, both are priced under $800,000, according to sources at the companies.

Results of the ADVANCE study, which were released in the closing hours of ACC19, emphasized the undercurrent that had flowed through ACC scientific sessions and across the exhibit floor — that the utility of CT was increasing within cardiology. The one-year outcome from the ADVANCE registry for CT-based fractional flow reserve (FFR) “show low rates of events in all patients, with less revascularization and a trend toward (a lower incidence of major adverse cardiac events) and significantly lower cardiovascular death or MI in patients.”

This means patients can use CT to determine if they have a low risk of adverse cardiovascular events. And the CT-based results will apply for as long as one year. The implication is that patients can safely skip invasive testing achieved through cardiac catheterization during that period.

 

Siemens Cardiac CT On ACC Exhibit Floor

Introduced on the ACC.19 exhibit floor and available for sale April 1, Siemens’ cardiac system is built on a platform initially unveiled at RSNA 2017. Siemens’ go.Top CT platform was cleared for marketing in the U.S. in early 2018 and has been in production ever since. “Because the production line exists today, there will be no delay in delivery (after sales of the cardiovascular edition begin April 1),” said Matthew Dedman, Siemens director of CT product marketing.

The CV version, shown for the first time at ACC.19, features applications designed exclusively for cardiological scanning, according to Dedman. 

“Historically cardiac CT was limited to the hospital environment because the technology had been expensive,” he said. By contrast, the CV-optimized go.Top allows “low total cost of ownership of our go platform and enables a high quality CT to be installed and utilized in the outpatient environment. This increases access to very valuable procedures, such as cardiac DT and additional FFR analysis.”

The 128-slice scanner is built particularly for outpatient cardiology offices, but might be installed in hospitals, as well, according to Dedman, who emphasized the ability of the scanner to gather data for coronary CTA, as well as for advanced tests, including CT-based FFR analyses by HeartFlow. Siemens developed a technical solution for the transmission of CT data from go.Top cardiovascular edition to HeartFlow, said Dedman, “for them to perform their analysis and transmit the results back to the physician.”

The system maintains, however, “the full radiological capability of the underlying go.Top,” he said. “So your traditional neuro, chest, abdomen and pelvis imaging could be performed on this machine as well.”

The tablet mounted on the side of the go.Top gantry allows technologist to set up scans from the CT table sides. This enables the tech to stay close to the patient — to help keep the patient calm and to achieve a low heart rate. “We know that probably the biggest factor in the success of the exam is patient cooperation,” Dedman said

The company’s CARE kV feature balances radiation dose and image contrast, automatically selecting the optimal kV setting for patients in increments of 10kV. In real-time, the system’s Check&GO algorithm helps identify problems with anatomical coverage and the distribution of media contrast.

 

GE Showcases Dedicated Cardiac CT At ACC

Although GE’s CardioGraphe was unveiled at an ACC meeting two years earlier, the company focused attention again on the CT, noting its dedication to cardiology and cost-effectiveness. “It is designed to serve the needs of the cardiologist and the radiologist who does cardiac CT,” Philippe Karam, GE’s global sales and marketing director, said. “We took all the features needed for true cardiac CT and put them in this scanner.”

The CardioGraphe, which evolved from a strategic partnership between GE Healthcare and Arineta LTD, was “built from the ground up,” Karam said. The compact system can be installed in 15 square meters. Dose efficiency is achieved using GE’s ASiR-CV. And it can be used to plan procedures including TAVR (transcatheter aortic valve replacement), according to Kira Behrens, GE’s director of premium CT for the U.S. and Canada.

The system is built for point-of-care scanning in an emergency department, a clinic (such as “a large interventional lab,” Behrens said, “where nuclear tests are frequently done”) or even a physician’s office, according to the company. In a single heartbeat, the CardioGraphe can create a 3-D image of the coronaries, valves, chambers and myocardium, as well as an angiogram of the aorta. Rotation speed is 0.24 seconds; single-beat heart coverage 140 mm, resolution 0.28 mm, according to the company.

 

Greg Freiherr is a contributing editor to Imaging Technology News (ITN) and Diagnostic and Interventional Cardiology (DAIC). Over the past three decades, Freiherr has served as business and technology editor for publications in medical imaging, as well as consulted for vendors, professional organizations, academia, and financial institutions.

 

Related content:

FDA Clears Siemens' Somatom go.All, go.Top CT Scanners 

VIDEO: Editor's Choice of Most Innovative New Cardiac CT Technology at SCCT 2017

New Cardiovascular CT Technology Entering the Market

Related Content

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Overlay Init